MARKET

WVE

WVE

Wave Life Scienc
NASDAQ
3.750
-0.160
-4.09%
After Hours: 3.750 0 0.00% 16:01 09/26 EDT
OPEN
3.850
PREV CLOSE
3.910
HIGH
3.980
LOW
3.560
VOLUME
457.15K
TURNOVER
0
52 WEEK HIGH
6.28
52 WEEK LOW
1.160
MARKET CAP
325.58M
P/E (TTM)
-1.8973
1D
5D
1M
3M
1Y
5Y
WAVE Life Sciences Chief Medical Officer Michael Panzara to Depart in October; Anne-Marie Li-Kwai-Cheung Promoted to Chief Development Officer
WAVE Life Sciences Chief Medical Officer Michael Panzara to Depart in October; Anne-Marie Li-Kwai-Cheung Promoted to Chief Development Officer
MT Newswires · 12h ago
Stitch Fix, Tellurian And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
U.S. stock futures traded slightly higher this morning after recording losses in the previous session. Here are some big stocks moving lower in today’s pre-market trading session.
Benzinga · 5d ago
Wave Life Sciences Touts Positive Update From Its Lead Huntington's Program
Wave Life Sciences Ltd (NASDAQ: WVE) announced an update to the ongoing Phase 1b/2a SELECT-HD trial of WVE-003 for Huntington's disease (HD).  Eighteen (18) participants have been dosed in the SELECT-HD trial.
Benzinga · 6d ago
BRIEF-Wave Life Sciences Announces Positive Update From Phase 1b/2a SELECT-HD Trial
BRIEF-Wave Life Sciences Announces Positive Update From Phase 1b/2a SELECT-HD Trial
Reuters · 6d ago
Wave Life stock rises as WVE-003 shows promise in interim data of Huntington's disease trial
Wave Life Sciences (NASDAQ:WVE) <a href="https://seekingalpha.co...
Seekingalpha · 6d ago
Wave Life Sciences Announces Update From Phase 1b/2a SELECT-HD Trial With Initial Results Indicating Allele-Selective Target Engagement With WVE-003 In Huntington's Disease
Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 or 60 mg; mean mHTT reduction across both cohorts was 22% (median
Benzinga · 6d ago
Wave Life Sciences to Host Analyst and Investor Virtual Event, “Towards the Clinic: Spotlight on RNA Editing for AATD,” on September 28, 2022
Focus on WVE-006, a first-in-class RNA editing development candidate for AATD, and feature AATD expert presentationCAMBRIDGE, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company commit...
GlobeNewswire · 09/16 12:30
WAVE Life Sciences's Return On Capital Employed Insights
Benzinga Pro data, WAVE Life Sciences (NASDAQ:WVE) reported Q2 sales of $375 thousand. Earnings fell to a loss of $41.30 million, resulting in a 9.21% decrease from last quarter.
Benzinga · 09/06 14:05
More
About WVE
Wave Life Sciences Ltd. is a Singapore-based clinical-stage genetic medicines company engaged in delivering life-changing treatments for people battling devastating diseases. It is engaged in developing oligonucleotides that target ribonucleic acid (RNA) and harness existing cellular machinery to reduce the expression of disease-promoting RNA or proteins, restore the production of functional proteins, or modulate protein expression. Its lead clinical development programs are designed to treat genetic diseases within the central nervous system (CNS), including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Huntington’s disease (HD), and muscular dystrophies, including Duchenne muscular dystrophy (DMD). Its programs include WVE-004 (silencing), its C9orf72 molecule for the treatment of C9orf72-associated ALS and FTD, WVE-003 (silencing), its mHTT SNP3 molecule for the treatment of HD, and WVE-N531 (splicing), its exon 53 molecule for the treatment of DMD.

Webull offers kinds of Wave Life Sciences Ltd stock information, including NASDAQ:WVE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, WVE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading WVE stock methods without spending real money on the virtual paper trading platform.